...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Metastatic breast cancer patients failing first-line, anthracycline-containing chemotherapy: is further therapy of benefit?
【24h】

Metastatic breast cancer patients failing first-line, anthracycline-containing chemotherapy: is further therapy of benefit?

机译：一线含蒽环类化疗失败的转移性乳腺癌患者：进一步治疗有益吗？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

During the last 50 years median survival for metastatic breast cancer has not varied and remains 2-3.5 years. To assess the clinical benefit of salvage systemic therapy a retrospective analysis of metastatic breast cancer patients all homogeneously treated with a commonly used first-line anthacycline-containing cytotoxic regimen (FEC) was undertaken. The 140 patients in this report were among 375 entered in two consecutive multicenter randomized trials carried out from Dec. 1983 to Jan. 1990. All patients died during follow-up. Median number of salvage therapies was 3 (range 1-7). Response rate (CR and PR) was 41% with FEC and 7%, 3%, 15%, 0%, 14%, 0%, 0% in patients receiving salvage treatment line 1 to 7, respectively. Time to treatment failure (TTF) was 7.5 months for FEC and 3.5, 2.5, 2.1, 1.6, 2.1, 1.1, 1.6 months at first to seventh salvage treatment, respectively. Only a very small fraction of patients receiving first-line FEC respond to subsequent palliative treatment. The advantages of salvage therapy are unclear and must be weighed against the inconvenience, cost and morbidity of treatment. After first salvage therapy, patients should be considered for randomized trials comparing systemic antineoplastic therapy with best palliative care. Endpoints of all future clinical trials in metastatic breast cancer should include measurement of quality of life and accurate, sequential measurement of symptom control.
机译：在过去的50年中，转移性乳腺癌的中位生存期没有变化，仍然为2-3.5年。为了评估挽救性全身疗法的临床益处，对所有均采用常用的一线含蒽环素的细胞毒性方案（FEC）进行了均一治疗的转移性乳腺癌患者进行了回顾性分析。本报告中的140例患者是1983年12月至1990年1月进行的两次连续多中心随机试验中的375例患者。所有患者在随访期间死亡。挽救疗法的中位数是3（范围1-7）。接受抢救治疗的1至7行患者，FEC的缓解率（CR和PR）分别为41％和7％，3％，15％，0％，14％，0％，0％。 FEC的治疗失败时间（TTF）为7.5个月，第一次至第七次挽救治疗分别为3.5、2.5、2.1、1.6、2.1、1.1、1.6个月。接受一线FEC的患者中只有极少数对随后的姑息治疗有反应。挽救疗法的优势尚不清楚，必须权衡治疗的不便，成本和发病率。首次抢救治疗后，应考虑将系统性抗肿瘤治疗与最佳姑息治疗相比较的患者进行随机试验。转移性乳腺癌的所有未来临床试验的终点应包括生活质量的测量和症状控制的准确，顺序的测量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号